COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)
01/02/2018
Reported sales were broadly unchanged at DKK 112 billion (2% growth in local currencies) Sales within diabetes care and obesity increased by 4% to DKK 92.9 billion (7% in local currencies). Sales of Tresiba ® increased [...]
Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma
01/02/2018
SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) announced today that it has received a milestone payment from the Company’s Chinese partner for eftilagimod alpha (IMP321), [...]
Sol-Gel Technologies Ltd. Announces Pricing of Initial Public Offering
01/02/2018
NESS ZIONA, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ: SLGL ), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and [...]
Harvard Bioscience Completes Acquisition of Data Sciences International
01/02/2018
HOLLISTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO ) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/02/2018
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to [...]
Aviragen Provides New Information Supporting Vote FOR Vaxart Merger
01/02/2018
Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA, Jan. 31, 2018 ( [...]
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
31/01/2018
Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with median duration of remission [...]
MPX Enters Into Management and Option Agreement With Dispensary in Baltimore, Maryland
31/01/2018
TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (the “ Company ” or “ MPX ”) (CSE:MPX) (OTC:MPXEF) is pleased to announce the Company, through its indirect wholly-owned subsidiary, S8 Management, [...]
Kane Biotech Announces Trading on the OTCQB Venture Market
31/01/2018
WINNIPEG, Manitoba, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE ), (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced that effective February 1, 2018 shares of the Corporation have [...]
Intellia Therapeutics to Present at February Healthcare Investor Conferences
31/01/2018
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will [...]
Golden Leaf Closes Bought Deal Private Placement
31/01/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (the “Company”, “Golden Leaf” or the “Issuer”) (CSE: [...]
Voyager Therapeutics Announces CEO Succession Plan for 2018
31/01/2018
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today [...]
Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome
31/01/2018
Study 1504 Top-Line Data on Track for 2Q 2018 EMERYVILLE, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous [...]
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007
31/01/2018
REGULATED INFORMATION PRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 31, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix [...]
Allscripts Names Dennis Olis Chief Financial Officer
31/01/2018
CHICAGO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX ) announced Dennis Olis has been named Chief Financial Officer of the Company, effective January 31, 2018. Since May of 2017 [...]
Nuvectra™ Announces Proposed Follow-On Stock Offering
31/01/2018
PLANO, Texas, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its [...]
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
31/01/2018
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company [...]
Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
31/01/2018
Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands company’s [...]
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
31/01/2018
First Regulatory Filing for the eNOGenerator System Expected By End of 2018 NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing [...]

Pages